3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
23
Recurrence
3
Neoplasms, Plasma Cell
2
Smoldering Multiple Myeloma
1
Neoplasms
1
Neoplasm, Residual
1
Immunoglobulin Light-chain Amyloidosis
1
Hematologic Neoplasms
1
Hematologic Diseases
1
Interventions
fludarabine phosphate
4
Cyclophosphamide
4
blinatumomab
3
Rituximab
3
Lenalidomide
2
Immunotherapy, Adoptive
2
venetoclax
1
trastuzumab deruxtecan
1
tisagenlecleucel
1
pembrolizumab
1
obinutuzumab
1
niraparib
1
nilotinib
1
isatuximab
1
acalabrutinib
1
Zymosan
1
Whole-Body Irradiation
1
Trastuzumab
1
Sodium Chloride
1
Sirolimus
1
Radiotherapy
1
Pentostatin
1
NKTR-255
1
Mycophenolic Acid
1
Melphalan
1
Magnetic Resonance Imaging
1
Immunotherapy
1
Imatinib Mesylate
1
Histamine Antagonists
1
Exercise Test
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Neoplasm, Residual
×
isatuximab
×
Clear all
NCT05690984
2026-03-16
EMAT
Medical College of Wisconsin
Phase 2
Active not recruiting
30 enrolled